HHGC
ESLA icon

Hunting Hill Global Capital’s Estrella Immunopharma ESLA Stock Holding History

Hunting Hill Global Capital’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-21,358
Closed -$26.5K – 112
2024
Q1 		$26.5K Hold
21,358
– – 0.01% 103
2023
Q4 		$23.7K Buy
+21,358
New +$32.3K 0.01% 101
2023
Q3 		– Sell
-289,548
Closed -$3.14M – 117
2023
Q2 		$3.14M Hold
289,548
– – 1.01% 16
2023
Q1 		$3.06M Hold
289,548
– – 2.4% 11
2022
Q4 		$2.98M Hold
289,548
– – 1.94% 10
2022
Q3 		$2.91M Hold
289,548
– – 1.73% 13
2022
Q2 		$2.9M Hold
289,548
– – 2.66% 10
2022
Q1 		$2.9M Hold
289,548
– – 2.39% 10
2021
Q4 		$2.87M Buy
289,548
+263,262
+1,002% +$2.61M 0.72% 15
2021
Q3 		$260K Buy
+26,286
New +$259K 0.08% 50

Other funds holding ESLA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ASM
ATW SPAC Management New York $79.2M AUM 10.67% 1-Year Est. Return
MCP
Maso Capital Partners Hong Kong $60.9M AUM 0.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Hunting Hill Global Capital's ESLA Position: Q2 2024 in Review

Hunting Hill Global Capital sold out of Estrella Immunopharma (ESLA) in Q2 2024, closing a stake of 21,358 shares — an estimated $26.5K sold.

Hunting Hill Global Capital first reported a position in ESLA in Q3 2021 and held it in 10 quarters. The position peaked at $3.14M in Q2 2023. 7 funds tracked by Wall St. Rank hold ESLA as of Q2 2024.

  • Hunting Hill Global Capital reported no remaining Estrella Immunopharma position as of Q2 2024 after selling out during the quarter.
  • Hunting Hill Global Capital sold 21,358 Estrella Immunopharma shares in Q2 2024, an estimated $26.5K.
  • Hunting Hill Global Capital first reported a position in Estrella Immunopharma in Q3 2021 and held it in 10 quarters.
  • Hunting Hill Global Capital's Estrella Immunopharma position peaked at $3.14M in Q2 2023.
  • 7 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q2 2024.

Based on Hunting Hill Global Capital's 13F filing for Q2 2024, filed 17 Jul 2024.